Brickell Biotech Inc.

---

Brickell Bio sells off rights to excessive-sweating drug for $9M upfront

 May 4, 2022 5:34:01 pm

---

Brickell’s losses mount as firm struggles with Nasdaq listing

 March 15, 2022 8:36:58 pm

---

Brickell Biotech acquires exclusive rights for Japanese autoimmune disease treatment

 February 2, 2022 10:01:37 pm

---

Brickell Biotech gets temporary delisting reprieve from Nasdaq

 December 15, 2021 8:28:24 pm

---

Brickell loses $13M on FDA prep, new drug platform

 November 9, 2021 10:07:16 pm

---

Brickell raises $8.9M on new common shares

 November 2, 2021 6:11:10 pm

---

Brickell adds 26M shares to market

 October 28, 2021 9:01:04 pm

---

Brickell plans to submit new drug application to FDA for gel

 October 7, 2021 5:37:00 pm

---

Brickell buys drug prospect, adds new CMO

 September 1, 2021 1:27:40 pm

---

Brickell Biotech completes Phase 3 tests for excessive sweating treatment

 August 16, 2021 9:32:40 pm

« Previous Page — Next Page »